Conversations in Healthcare

Conversations in Healthcare

By ClarivateNewsBusiness News
Download on the App Store

Conversations in Healthcare episodes

  • Best practices for university - healthcare partnerships: Learnings from the Institute of Cancer Research

    In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Dr. Toby Richardson, who is Head of Business Development and Licensing; Deputy Director of Business and Innovation at The Institute of Cancer Research. Mike and Toby discuss how research collaborations between the ICR and biopharma companies help the Institute achieve its mission to make the discoveries that defeat cancer. Learn more in the full episode.



    Hosted on Acast. See acast.com/privacy for more information.

    28 min
  • Best practices for university – healthcare partnerships: Learnings from Oxford

    In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Dr. Phil Clare, the Deputy Director, Research Services (Knowledge Exchange and Engagement) at the University of Oxford. Mike and Dr. Clare discuss the key role that university research plays in shaping new medicines and technologies, and what that process looks like. Learn more in the full episode.




    Hosted on Acast. See acast.com/privacy for more information.

    36 min
  • The evolution of the asset-centric approach in biotech venture capital
    In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Francesco De Rubertis, a co-founder and managing partner at Medicxi, one of the most prominent financial supporters of innovative biotech activity. Francesco provides insights into how the biotech venture capital model has evolved in the past decades to an asset-centric approach, and discusses Centessa, which recently secured $250m in funding. Learn more in the full episode.

    Hosted on Acast. See acast.com/privacy for more information.

    48 min
  • Drugs to Watch 2021
    Clarivate market experts break down the opportunities and potential threats for 2021’s Drugs to Watch – the key drugs expected to be blockbusters by 2026.

    Hosted on Acast. See acast.com/privacy for more information.

    24 min
  • How Glympse Bio oversubscribed their Series B funding amidst the pandemic
    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Dr. Caroline Loew, President and CEO from Glympse Bio. They discuss the biotech’s focus on both disease detection and response to treatment using bioengineered sensors, starting with NASH. Dr. Loew also shares career advice for moving from pharma to biotech and how she pivoted the company’s narrative during a funding round at the bottom of the pandemic-related stock market crash.

    Hosted on Acast. See acast.com/privacy for more information.

    45 min
  • A novel approach to treating neurodegenerative disease
    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Dr. Leen Kawas, president and CEO of Athira Pharma. Dr. Kawas shares the company’s innovative approach to treating Alzheimer’s disease by developing small molecules to restore neuronal health and stop neurodegeneration. They also discuss Athira’s recent IPO following a successful series B funding round, all during the pandemic. 

    Hosted on Acast. See acast.com/privacy for more information.

    27 min
  • Pivoting a product launch during the pandemic
    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Bryan Witherbee, President & CEO of Adarza BioSystems. Earlier this year, Adarza raised 25 million dollars to support the full commercialization of Ziva, an automated biological platform which delivers comprehensive, high definition, protein biomarker profiles. Although their launch plans were disrupted by the pandemic, Bryan shares how Adarza responded to the challenge by utilizing Ziva for COVID-19 research.

    Hosted on Acast. See acast.com/privacy for more information.

    36 min
  • Utilizing pluripotent stem cells in cell therapy
    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Brian Culley, CEO of Lineage Cell Therapeutics. Brian and Mike discuss the company’s cell therapy program, utilizing pluripotent stem cells, initially targeting dry age-related macular degeneration, acute spinal cord injuries, and non-small cell lung cancer. Brian shares about the status of their Phase 1/2a clinical trials, and how COVID-19 has affected the company’s operations.

    Hosted on Acast. See acast.com/privacy for more information.

    26 min
  • Possible treatment for COVID-19 related respiratory failure
    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Jonathan Javitt, CEO of NeuroRx. Dr Javitt discusses how NeuroRx is working in collaboration with Relief Therapeutics on Aviptadil, a synthetic version of vasoactive intestinal peptide, and a potential treatment of COVID-19 related respiratory failure. Dr. Javitt shares the promising results of an open label study of the drug, and the company’s plans if trials are successful.

    Hosted on Acast. See acast.com/privacy for more information.

    22 min
  • COVID-19, multi-stem clinical trials and a new way of fundraising
    In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Gil Van Bokkelen, founder, chairman and CEO of Athersys Inc. They discuss the company’s clinical program that is focusing on a special class of stem cells which display very unique properties and have been obtained from healthy young consenting donors. Mike and Gil talk about how Athersys was already working on an approach to treat patients with acute respiratory distress syndrome before the pandemic emerged and the challenges they face to tackle their COVID-19 strategy. Also, Gil shares how Athersys was successful in raising nearly $58m in April and what he thinks the company needs to do to become a multibillion-dollar company.

    Hosted on Acast. See acast.com/privacy for more information.

    51 min

About Conversations in Healthcare

From the publisher's feed

Clarivate Conversations in Healthcare is a collection of candid interviews with key leaders and experts. Veteran industry journalist Mike Ward explores business challenges and opportunities the…